Study on the Effect and Mechanism of Percutaneous Auricular Electrical Stimulation in Preventing Central Sensitization Pain in Comorbid Rheumatoid Arthritis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorGuang'anmen Hospital of China Academy of Chinese Medical Sciences

About this trial

This multicenter, randomized, double-blind, sham-controlled trial aimed to evaluate the preventive efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) against central-sensitization-related pain in high-risk rheumatoid arthritis (RA) patients. A total of 124 eligible participants were randomized 1:1 to receive 4-week home-based real or sham taVNS. The primary outcome was the change in Central Sensitization Inventory-9 (CSI-9) score from baseline to week 4. Peripheral blood, faecal samples and brain MRI were collected to explore potential brain-gut-microbiome-related mechanisms. Our findings will provide high-quality evidence for this non-pharmacological intervention for RA-related central sensitization pain.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • taVNS

    Device

    Treatment using the Huatuo electronic acupuncture device (model SDZ-IIB) with electrodes placed on the auricular points related to the heart and kidney. Pulsed wave type is sparse-dense wave, with a frequency of 20Hz and intensity set to the highest level tolerable without pain. Patients will perform self-treatment at home for 30 minutes, twice daily, for 5 days a week over 4 weeks.

  • Sham Stimulation

    Device

    Treatment using the same Huatuo electronic acupuncture device with electrodes placed on different ear points (over the ear helix). The device settings (pulse type, frequency, intensity) are the same as the experimental group but do not correspond to traditional acupuncture points. Patients will also perform self-treatment at home as per the same schedule as the experimental group.

Treatment groups

124 Participants
are divided into 2 treatment groups
Group A: Experimental groupExperimental treatment 1 intervention
Group B: Control groupSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change from baseline in Central Sensitization Inventory-9 (CSI-9) score at Week 4 of treatment.

The Central Sensitization Inventory-9 (CSI-9), a 9-item short-form self-report questionnaire derived from CSI-25, is used to assess symptoms of central sensitization in patients with chronic pain

Time frame
baseline, Week 4 (end of treatment), and Week 8 (follow-up)

Secondary outcomes

1

Visual Analogue Scale (VAS) for pain

The Visual Analogue Scale (VAS) for pain is a widely-used self-reported unidimensional tool to quantify the subjective intensity of clinical pain.

Time frame
baseline, Week 4 (end of treatment), and Week 8 (follow-up)
2

Polysymptomatic Distress Scale (PDS)

The Polysymptomatic Distress Scale (PDS) evaluates widespread somatic symptom burden and is commonly applied for screening and assessing fibromyalgia-related symptomatology.

Time frame
baseline, Week 4 (end of treatment), and Week 8 (follow-up)
3

Brief Pain Inventory (BPI)

The Brief Pain Inventory (BPI) is a validated questionnaire measuring pain severity and pain-related interference with daily function in patients with chronic pain conditions.

Time frame
baseline, Week 4 (end of treatment), and Week 8 (follow-up)
4

Fibromyalgia Impact Questionnaire-Revised (FIQR)

The Fibromyalgia Impact Questionnaire-Revised (FIQR) assesses overall disease impact including physical function, symptoms and quality of life among patients with fibromyalgia-like chronic pai

Time frame
baseline, Week 4 (end of treatment), and Week 8 (follow-up)

Other outcomes

1

Semi-Quantitative Food Frequency Questionnaire (SFFQ)

The Semi-Quantitative Food Frequency Questionnaire (SFFQ) captures habitual dietary intake and food consumption frequency for nutritional and epidemiological research.

Time frame
baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Lead sponsor

Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

Collaborator

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Collaborator

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Collaborator

Sichuan Province Orthopetic Hospital

Collaborator

Inner Mongolia Hospital of Traditional Chinese Medicine

Collaborator

Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Collaborator

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Collaborator

Shenzhen traditional Chinese medical hospital

Collaborator

Centre Hospitalier Universitaire de Saint Etienne

Collaborator

This trial is not recruiting at the moment. You can still explore other options: